( CDIC) posted a loss of $644,000, or a penny a share, for the first quarter ended Feb 28, reversing a profit of $761,000, or 2 cents a share, a year ago. Revenue for the quarter was $9.7 million. Analysts were expecting the company to break even on revenue of $10.3 million, according to Thomson First Call. The stock was down 3 cents, or 1.05%, to $2.82 in after-hours trading.
Bed Bath & Beyond
said it earned $181 million, or 59 cents a share, for the fourth quarter ended Feb. 26, up from $144.2 million, or 47 cents a share, a year ago. Sales for the quarter increased 13% to $1.47 billion, while same-store sales rose 5.1%. Analysts were expecting earnings of 55 cents a share on sales of $1.45 billion. The stock was up $2.12, or 5.77%, to $38.86 in after-hours trading.
announced that its investigational HPV vaccine significantly reduced infection and diseases, including new cervical pre-cancers and genital warts, in a new clinical phase II study, compared to a placebo. The stock was up 2 cents, to $32.91.
announced that it has acquired three dialysis programs, two in Michigan and one in Oregon. The three outfits serve more than 400 patients. The company did not disclose the terms of the transactions. The stock was unchanged at $38.31.
( AEOS) said that March total sales rose 38.5% to $184.6 million, compared with $133.3 million a year ago. Same-store sales rose 29.2%. The company also raised its first-quarter earnings outlook to 30 cents to 31 cents a share, up from the range of 26 cents to 27 cents a share. The stock was up 81 cents, or 2.68%, to $30.99 in after-hours trading.
( ELAB) said that it has received final approval for its Gabapentin capsules, the generic version of Neurontin capsules, which are used to treat postherpetic neuralgia. The company will begin shipping the product immediately. The company also said it received final approval for the generic version of the urinary tract treatment Macrobid, made by
Proctor & Gamble
. Eon Labs was down 4 cents, or 0.13%, to $30.29 in after-hours trading, while Proctor & Gamble was down 2 cents, or 0.04%, to $53.94.